By using the propensity score to match SGLT2 inhibitor users (n = 22,830) to users of other hypoglycemic drugs (n = 68,490), the study found that compared with other hypoglycemic drugs, the SGLT2 inhibitors decreased major adverse cardiovascular events (HR 0.78, 95% CI 0.69–0.87, p < 0.0001), cardiovascular disease mortality (HR 0.53, 95% CI 0.40–0.71, p < 0.0001), and hospital events due to heart failure (HR 0.70, 95% CI 0.61–0.81, p < 0.0001) (38). This evidence concerns the gene SLC5A2 and cardiovascular disorder.